Power Law company profile

Ultima Genomics

Health Tech & Medtech · Newark, United States · Founded 2016 Unicorn

DNA sequencing with its UG 100™ platform, delivering ultra‑high throughput and cost‑effective omics solutions that aim to make the $100 genome a reality

Valuation

$2.5–5B

Latest valuation · 2026

Unlock exact value

Revenue

$10–50M

Latest reported FY

Unlock exact value

Headcount

100–500

Current team size

Unlock exact value

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

10 investors on Ultima Genomics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 2 investors entered at this stage

Khosla Ventures

Lightspeed Venture Partners

Series B+ 8 investors entered at this stage

aMoon Fund

Playground Global

Marius Nacht

Global footprint

Where Ultima Genomics has talent and traffic

AI talent share

3.6% of workforce is AI talent
(11 of 302 staff)

Core AI51.66%

Other AI61.99%

Non-AI workforce29196.36%

Workforce by country

7 countries with
team presence

🇺🇸 United States79.4%

🇮🇱 Israel16.2%

🇬🇧 United Kingdom2.3%

🇨🇦 Canada0.7%

🇳🇱 Netherlands0.4%

Top 5 of 7 shown

Web traffic by country

15K monthly visits
across markets

🇺🇸 United States58.7%

🏳️ Korea17.3%

🏳️ Republic of8%

🇮🇱 Israel6.7%

🇮🇳 India6%

Top 5 markets shown

Patent intelligence

$31M patent portfolio · 65 active families

Estimated portfolio value

$31M

0.85% of valuation · 9.5× smaller than top peer MGI Tech ($292M)

65 active patent families

Where Ultima Genomics innovates Molecular biologyBioinformaticsNucleic acid moleculeNucleotideComputational biology

Where Ultima Genomics concentrates vs peers

Each axis is a top-10 topic across Ultima Genomics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Ultima Genomics

An AI-synthesized read of the highest-engagement posts about Ultima Genomics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ultima Genomics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles